VeriSIM Life is an AI-driven translational modeling company developing human-centric new approach methodologies (NAMs) that integrate mechanistic computational modeling with advanced in vitro systems to improve drug development decision-making. For this challenge, VeriSIM leads the integration of patient-derived uterine organoid pharmacodynamic data with hybrid mechanistic and AI-based modeling to predict human-relevant efficacy and therapeutic index, reducing reliance on early rodent screening in women’s health indications such as endometriosis and uterine fibroids.
